Form 4: Microbot Medical Executive Sharon Simon Acquires Options
SEC Form 4 Filing
Sharon Simon, General Manager and CTO of Microbot Medical Inc., reports the acquisition of stock options.
Summary
- On February 5, 2025, Sharon Simon, General Manager and CTO of Microbot Medical Inc., filed a Form 4.
- The form details the acquisition of stock options.
- Simon acquired 43,750 stock options with an exercise price of $2.04.
- These options vest starting August 5, 2025, with 25% vesting initially and the remaining 75% vesting quarterly over the next 30 months.
- Simon also acquired 8,750 stock options with an exercise price of $1.25, which vested on February 5, 2025, after performance milestones were met.
- These options were originally granted on February 26, 2024.
- Following these transactions, Simon directly owns 43,750 stock options with an exercise price of $2.04 and 8,750 stock options with an exercise price of $1.25.
Sentiment
Score: 6
Explanation: The document is a neutral disclosure of stock option grants. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information about executive compensation.
Positives
- The vesting of performance-based options suggests that the company is achieving its milestones.
- The acquisition of options by a key executive could be seen as a positive sign of their confidence in the company's future.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It provides transparency into the equity-based compensation of key personnel.
Comparison to Industry Standards
- Stock option grants are a common form of compensation for executives in the medical device industry.
- Vesting schedules, such as the one described in the document, are typical for aligning executive incentives with long-term company performance.
- Companies like Intuitive Surgical, Medtronic, and Stryker also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- The acquisition of stock options by a key executive could be viewed positively by shareholders as it aligns the executive's interests with the company's long-term success.
- Employees may view this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date performance-based options were granted. |
| 02/05/2025 | Date of transaction and vesting of performance-based options. |
| 02/05/2025 | Date the Compensation Committee confirmed that milestones were met for 8,750 options. |
| 08/05/2025 | Date when 25% of the 43,750 options will vest. |
| 02/26/2034 | Expiration date of the 8,750 options. |
| 02/05/2035 | Expiration date of the 43,750 options. |
| 02/07/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.